Literature DB >> 27538993

JC virus infection is acquired very early in life: evidence from a longitudinal serological study.

Francesca Elia1, Sonia Villani1, Federico Ambrogi2, Lucia Signorini1, Simone Dallari1, Sandro Binda3, Valeria Primache3, Laura Pellegrinelli3, Pasquale Ferrante1,4, Serena Delbue5.   

Abstract

JC virus (JCV) is a widespread member of the Polyomaviridae family. Following primary infection, which occurs asymptomatically during childhood, JCV establishes latency in the host. JCV seroprevalence can reach 80 % in healthy adults, but the age of viral exposure has not been yet characterized. This study was conducted to define JCV seroprevalence in Italian infants and to estimate the date of primary infection. A JCV viral protein 1 (VP1)-GST fusion protein was used in conjunction with a homemade indirect enzyme-linked immunosorbent assay (ELISA) to test for the presence of IgG antibodies to JCV in 981 serum samples collected from 644 Italian infants of different ages (1 day to 3 years old) and in 102 breast milk samples. IgM antibody presence was also evaluated in longitudinally collected samples from 17 selected children. JCV antibody prevalence and normalized optical density (nOD) were calculated. For the longitudinal analysis, generalized estimating equation techniques and spline functions were used to estimate the possible non-linear effects of time on antibody production kinetics. JCV IgG was detected in 71.8 % of the sera. Prevalence increased over time from 46.1 % (1 month old) to 80.7 % (12 months old), 85.9 % (24 months old), and 85.5 % (36 months old). As determined by nOD, the longitudinal analysis of serum IgG amounts in children of this study (ages 1 day to 3 years old) illustrated IgG kinetic changes with statistically significant trends (p = 0.001). One-month-old children were largely negative for JCV IgM (82.4 %), and 58.8 % of children produced JCV IgM within the second and sixth months of life. JCV IgG was detected in 27.3 % of breast milk samples. JCV primary infection likely occurs before 6 months of age, and a sizeable percentage of Italian infants will become JCV seropositive within 2 years of age. This study can be used to determine the optimal age for potential future JCV vaccination in infants.

Entities:  

Keywords:  JC polyomavirus; Newborns; Primary infection; Seroprevalence

Mesh:

Substances:

Year:  2016        PMID: 27538993     DOI: 10.1007/s13365-016-0477-9

Source DB:  PubMed          Journal:  J Neurovirol        ISSN: 1355-0284            Impact factor:   2.643


  32 in total

1.  VP1 pseudocapsids, but not a glutathione-S-transferase VP1 fusion protein, prevent polyomavirus infection in a T-cell immune deficient experimental mouse model.

Authors:  Andrea Vlastos; Kalle Andreasson; Karin Tegerstedt; Dana Holländerová; Shirin Heidari; Jitka Forstová; Torbjörn Ramqvist; Tina Dalianis
Journal:  J Med Virol       Date:  2003-06       Impact factor: 2.327

Review 2.  Lessons from immune responses and vaccines against murine polyomavirus infection and polyomavirus-induced tumours potentially useful for studies on human polyomaviruses.

Authors:  Torbjörn Ramqvist; Tina Dalianis
Journal:  Anticancer Res       Date:  2010-02       Impact factor: 2.480

3.  Prevalence of anti-rubella, anti-measles and anti-mumps IgG antibodies in neonates and pregnant women in Catalonia (Spain) in 2013: susceptibility to measles increased from 2003 to 2013.

Authors:  P Plans; F de Ory; M Campins; E Álvarez; T Payà; E Guisasola; C Compte; K Vellbé; C Sánchez; M J Lozano; I Aran; A Bonmatí; R Carreras; M Jané; L Cabero
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-02-10       Impact factor: 3.267

4.  Development of a DNA vaccine targeting Merkel cell polyomavirus.

Authors:  Qi Zeng; Bianca P Gomez; Raphael P Viscidi; Shiwen Peng; Liangmei He; Barbara Ma; T-C Wu; Chien-Fu Hung
Journal:  Vaccine       Date:  2011-12-29       Impact factor: 3.641

5.  Kinetics of maternal antibodies against rubella and varicella in infants.

Authors:  E Leuridan; N Hens; V Hutse; M Aerts; P Van Damme
Journal:  Vaccine       Date:  2010-06-15       Impact factor: 3.641

6.  Human polyomavirus JC virus genome.

Authors:  R J Frisque; G L Bream; M T Cannella
Journal:  J Virol       Date:  1984-08       Impact factor: 5.103

7.  Seroepidemiology of the human polyomaviruses.

Authors:  Annika Stolt; Kestutis Sasnauskas; Pentti Koskela; Matti Lehtinen; Joakim Dillner
Journal:  J Gen Virol       Date:  2003-06       Impact factor: 3.891

8.  Waning of maternal antibodies against measles, mumps, rubella, and varicella in communities with contrasting vaccination coverage.

Authors:  Sandra Waaijenborg; Susan J M Hahné; Liesbeth Mollema; Gaby P Smits; Guy A M Berbers; Fiona R M van der Klis; Hester E de Melker; Jacco Wallinga
Journal:  J Infect Dis       Date:  2013-05-08       Impact factor: 5.226

9.  Seroepidemiology of Human Polyomaviruses in a US Population.

Authors:  Anala Gossai; Tim Waterboer; Heather H Nelson; Angelika Michel; Martina Willhauck-Fleckenstein; Shohreh F Farzan; Anne G Hoen; Brock C Christensen; Karl T Kelsey; Carmen J Marsit; Michael Pawlita; Margaret R Karagas
Journal:  Am J Epidemiol       Date:  2015-12-13       Impact factor: 4.897

10.  Seroepidemiology of human polyomaviruses.

Authors:  Jaime M Kean; Suchitra Rao; Michael Wang; Robert L Garcea
Journal:  PLoS Pathog       Date:  2009-03-27       Impact factor: 6.823

View more
  7 in total

1.  Anti-JC virus antibody sera positivity and index value among patients with multiple sclerosis may be correlated with age, sex, and area of residence.

Authors:  Sogol Koolaji; Narges Sistany Allahabadi; Arash Ahmadi; Sharareh Eskandarieh; Abdorreza Naser Moghadasi; Amir Reza Azimi; Mohammad Ali Sahraian
Journal:  J Neurovirol       Date:  2018-05-21       Impact factor: 2.643

2.  Fatal ruxolitinib-related JC virus meningitis.

Authors:  Begoña Ballesta; Héctor González; Vicente Martín; Juan J Ballesta
Journal:  J Neurovirol       Date:  2017-08-08       Impact factor: 2.643

3.  Antibody response to polyomavirus primary infection: high seroprevalence of Merkel cell polyomavirus and lymphoid tissue involvement.

Authors:  Carolina Cason; Lorenzo Monasta; Nunzia Zanotta; Giuseppina Campisciano; Iva Maestri; Massimo Tommasino; Michael Pawlita; Sonia Villani; Manola Comar; Serena Delbue
Journal:  J Neurovirol       Date:  2018-01-12       Impact factor: 2.643

Review 4.  Review on the role of the human Polyomavirus JC in the development of tumors.

Authors:  Serena Delbue; Manola Comar; Pasquale Ferrante
Journal:  Infect Agent Cancer       Date:  2017-02-03       Impact factor: 2.965

Review 5.  Human Polyomavirus JCPyV and Its Role in Progressive Multifocal Leukoencephalopathy and Oncogenesis.

Authors:  Luis Del Valle; Sergio Piña-Oviedo
Journal:  Front Oncol       Date:  2019-08-08       Impact factor: 6.244

Review 6.  The oncogenic roles of JC polyomavirus in cancer.

Authors:  Hua-Chuan Zheng; Hang Xue; Cong-Yu Zhang
Journal:  Front Oncol       Date:  2022-09-23       Impact factor: 5.738

Review 7.  The Role of the JC Virus in Central Nervous System Tumorigenesis.

Authors:  Nicholas Ahye; Anna Bellizzi; Dana May; Hassen S Wollebo
Journal:  Int J Mol Sci       Date:  2020-08-28       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.